Production of Plant-Derived Oleuropein Aglycone by a Combined Membrane Process and Evaluation of Its Breast Anticancer Properties

Rosalinda Mazzei*, Emma Piacentini¹, Monica Nardi², Teresa Poerio¹, Fabio Bazzarelli¹, Antonio Procopio², Maria Luisa Di Gioia², Pietro Rizza*, Rosangela Ceraldi², Catia Morelli², Lidietta Giorno¹ and Michele Pellegrino²

¹ Institute on Membrane Technology, National Research Council, ITM-CNR, Rende, Italy, ² Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy

Natural products and herbal therapies represent a thriving field of research, but methods for the production of plant-derived compounds with a significative biological activity by synthetic methods are required. Conventional commercial production by chemical synthesis or solvent extraction is not yet sustainable and economical because toxic solvents are used, the process involves many steps, and there is generally a low amount of the product produced, which is often mixed with other or similar by-products. For this reason, alternative, sustainable, greener, and more efficient processes are required. Membrane processes are recognized worldwide as green technologies since they promote waste minimization, material diversity, efficient separation, energy saving, process intensification, and integration. This article describes the production, characterization, and utilization of bioactive compounds derived from renewable waste material (olive leaves) as drug candidates in breast cancer (BC) treatment. In particular, an integrated membrane process [composed by a membrane bioreactor (MBR) and a membrane emulsification (ME) system] was developed to produce a purified non-commercially available phytotherapic compound: the oleuropein aglycone (OLA). This method achieves a 93% conversion of the substrate (oleuropein) and enables the extraction of the compound of interest with 90% efficiency in sustainable conditions. The bioderived compound exercised pro-apoptotic and antiproliferative activities against MDA-MB-231 and Tamoxifen-resistant MCF-7 (MCF-7/TR) cells, suggesting it as a potential agent for the treatment of breast cancer including hormonal resistance therapies.

Keywords: oleuropein aglycone, membrane bioreactor, membrane emulsification, breast cancer, integrated membrane systems
INTRODUCTION

Breast cancer (BC) is a disease that features several morphological aspects, different therapeutic responses, and variable clinical outcomes. In industrialized countries, it represents the most common cause of death in women (Ferlay et al., 2015; Kohler et al., 2015). Current therapeutic cancer treatments are based on various methods including surgical removal, radiotherapy, chemotherapy, biological therapy, and hormone therapy. The side effects of these therapies are innumerable, and some of them are related to the cytotoxic activity of drugs that act indistinctly both on cancer cells and on healthy ones. The severe side effects of these therapies, such as nausea, vomiting, diarrhea, mucositis, and myelosuppression decrease the quality of life of the patients (Sharma et al., 2005). Moreover, increasing instances of tumors with resistance to current therapeutic compounds has become a problematic issue, which has pushed research toward new anticancer agents (Vidal et al., 2014; Carnero et al., 2016).

In the last few decades, vegetal products have been recognized as effective and economic sources of new synthetic therapeutic compounds and many scientists have started to focus their research on this sector (Cragg and Newman, 2013; Omogbadegun, 2013). One of the main strategies adopted by these researchers addresses the need to find synthetic routes for these vegetal products using sustainable technologies (Woodley, 2008; Abdelraheem et al., 2019).

Membrane-based technologies and in particular membrane bioreactors (MBRs) (Mazzei et al., 2009, 2010a, 2013; Giorno et al., 2013; Macedonio and Drioli, 2017) are widely recognized as more ecological processes of engineering since they fulfill the different criteria which make them more “green,” such as equipment size, energy consumption, process flexibility, and so forth. MBRs are also widely investigated in the pharmaceutical application for the production of different drugs (Mazzei et al., 2010b, Mazzei et al., 2017; Piacentini et al., 2017).

In our previous works, the oleuropein aglycone (OLA) was produced using different MBRs systems. OLA is a vegetal product with many therapeutic applications due to its antihyperglycemic, anti-Alzheimer disease, anti-inflammatory, antioxidant, and other properties (Galiano and Villalain, 2015). In particular, it was produced by the enzymatic (β-glucosidase) hydrolysis of oleuropein (OLE) extracted from olive leaves (Mazzei et al., 2010b, 2012; Ranieri et al., 2018; Piacentini et al., 2019). In the above-mentioned MBRs, the enzyme was immobilized within the membrane and the maximum conversion achieved was 60%. As a consequence, the recovered OLA was not purified from the substrate, since unconverted OLE was also present in the collected solution. In the batch system, the co-product glucose also promotes a competitive inhibition, as already reported in Ranieri et al. (2018).

For OLA formation occurring after β-glucosidase action (Scheme in Figure 1), the aglyconic product (A) is highly unstable and rearranges in different isomers (De Nino et al., 2000; Di Donna et al., 2011). It undergoes an isomerization process that leads to the formation of monoaldehyde (B), dialdehyde (C), geminal diol (D), and dihydropyran (E) characterized by their interaction with other lipids.

Several studies (in vitro and in vivo) have reported the antiproliferative and proapoptotic effects of OLE (Sirianni et al., 2010; Casaburi et al., 2013; Barbaro et al., 2014; Abtin et al., 2018; Antognelli et al., 2019; Bayat et al., 2019; Liu et al., 2019). Particularly, it has been demonstrated that OLE can show apoptotic effects in a human MCF-7 cell line (Han et al., 2009). However, there is a common consensus that OLA could have a higher therapeutic effect than OLE, due to its higher hydrophilic character, which allows interaction directly with biological membranes (Galiano and Villalain, 2015), increasing its local concentration (Leri et al., 2016) and its beneficial pharmacological effect on cells.

Oleuropein aglycone is not yet commercially available as a pure compound and just a few studies have reported the potential of the compound on BC treatment (Impellizzeri et al., 2011; Pantano et al., 2017; Xu et al., 2018), when in combination with the other polyphenols extracted from extra virgin olive oil (EVOO) (Menendez et al., 2008) or using the single compound on MCF-7, SKBR3, and MCF-7/(pBABE)HER2 cells. Among the different polyphenols from EVOO (tyrosol, hydroxytyrosol), OLA, which was separated from the other polyphenols by a semi-preparative reverse-phase high-performance liquid chromatography, showed the best performance in decreasing BC cell viability (Menendez et al., 2007). The mentioned article highlighted the higher anticancer properties of OLA than OLE toward BC cell lines. This work also proposed that the higher anticancer effect was attributed to the higher lipophilicity of the OLA than OLE, which permits improved incorporation in the cell membrane as well as better interaction with other lipids.

A sustainable production process for OLA must be studied to replace the expensive existing method of olive oil extraction, without altering its anticancer properties. Taking this into account, this is the first study to assess the biological activity of OLA produced by the integrated membrane process toward two different very aggressive BC cell lines, intending to verify if the production process could alter the anticancer properties
of this important phytotherapeutic compound. In particular, the potential cytotoxic effects of this bioderived compound on MDA-MB-231 triple-negative and MCF-7 tamoxifen resistant (MCF-7/TR) BC cell lines have been studied, to establish its possible mechanism of action.

The MDA-MB-231 cell line is a highly aggressive, invasive, and poorly differentiated triple-negative breast cancer (TNBC) cell line as it lacks estrogen receptor (ER) and progesterone receptor (PR) expression, as well as HER2 (human epidermal growth factor receptor 2) amplification. The MCF-7/TR is a tamoxifen-resistant cell line derived from the selection of parental ERα+ MCF-7 cells. The pro-apoptotic and antiproliferative activities of OLA against BC cells, regardless of ER status, have been demonstrated.

MATERIALS AND METHODS

Chemicals
β-glucosidase from almond (Cod. G4511) and the ethyl acetate were supplied by Sigma-Aldrich. Solvents for HPLC, NMR, LC-QTOF-MS (acetonitrile, methanol, dichloromethane, dimethyl sulfoxide, deuterated chloroform) were supplied by Carlo Erba and Sigma-Aldrich. NaH2PO4 and Na2HPO4, supplied by VWR, were used to prepare phosphate buffer (50 mM, pH 6.5) for enzymatic and substrate solutions. Bicinchoninic acid kit (BCA) was used to measure protein concentration, supplied by Sigma-Aldrich.

HPLC Analysis
The HPLC (Hewlett-Packard 2100) was equipped with a Rheodyne injector, a 20 µl loop, and a UV detector (280 nm) (Agilent Technologies Hewlett-Packard-Strasse 8, 76337, Waldbronn, Germany). The column used is a Phenomenex Jupiter C18 (250–4.6 mm, 5 µm) heated to 30°C with an elution gradient from 100% of H2O (5 min) to 35% of CH3CN (over 10 min), followed by 35–90% of CH3CN (5 min). The concentration of OLE and OLA in the samples coming from the integrated membrane process was measured by HPLC, by the method reported in Mazzei et al., 2012. A reverse silica C18 column (250–4.6 mm, 5 µm, Grace, Adsorbosphere XL) was used. A mixture of CH3CN/H2O (21:79) acidified with o-phosphoric acid (up to pH 3) was used as a mobile phase, injecting 5 µl of sample volume and setting the UV detector at 280 nm.

LC-QTOF-MS Analysis
An Agilent 6540 UHD Accurate-Mass LC-Q-TOF-MS (Agilent, Santa Clara, CA, United States) equipped with an Electrospray ionization source (Dual AJS ESI) operating in positive ion mode was used to carry out the analyses of ultra-high-pressure liquid chromatography (UPLC) combined with quadrupole time-of-flight mass spectrometry (Q-TOF-MS). We used a C18RP analytical column (Poroshell 120, SB-C18, 50 × 2.1 mm, 2.7 µm) heated to 30°C. For the analysis, we used an elution gradient from 5 to 95% of CH3CN [0.1% formic acid (FA) over 13 min] in an aqueous solution (0.1% FA), with a flow rate of 0.4 ml/min.

NMR Spectra
1H-NMR and 13C-NMR spectra were recorded at 300 MHz, and at 75 MHz, respectively, using a Bruker WM 300 system. The samples were solubilized in DMSO for OLE analysis or in CDCl3 for OLA analysis. Chemical shifts are given in parts per
Microwave-Assisted Extraction of Oleuropein From Olive Leaves

Coratina cultivar of Olea europaea leaves, supplied by “Consiglio per la ricerca in agricoltura e l’analisi dell’economia agraria (CREA),” were used as initial feedstock for oleuropein extraction. The sample was first dried at 50°C for 48 h, pulverized, and then kept at room temperature until use. One hundred grams of the obtained sample was suspended in water (800 ml) and placed in a Pyrex round-bottom flask (equipped with a jacketed coiled condenser) in a domestic microwave oven. After 10 min at 800 W, samples were filtered and the water solution was dried under reduced pressure by Heidolph Rotary Evaporator, Laborota 4000. The obtained dried sample was then washed with acetone and filtered and the solution was evaporated under reduced pressure. Pure oleuropein was obtained by purifying the crude product by liquid chromatography on a Supelco VersaFlash station. A silica cartridge and a mixture of CH₂/MeOH 8:2 as a mobile phase were used. The purified sample was analyzed by LC-Q-TOF-MS. By this method, a yield of pure oleuropein of 5% was obtained.

Combined Membrane Process to Produce Dry OLA

The integrated system to produce the dry OLA is composed of an MBR and a ME process (Figure 2). The MBR is composed of a stirred tank (ST) (50 mL) in which the enzymatic reaction occurred (37°C) and a flat ultrafiltration membrane (30 kDa, regenerated cellulose membrane, diameter 47 mm, Millipore) to separate the produced OLA from the enzyme. Inlet and outlet pressure were measured by digital pressure gauges (Keller). A thermostated jacket was used to thermally control (37°C) the MBR unit. The oleuropein powder and enzyme were dissolved in 50 mM phosphate buffer (pH 6.5). The initial oleuropein solution concentration is 2.5 mM, while the enzyme concentration is 3.8·10⁻² mM (10 mg).

After each reaction cycle in the STR, the solution was ultrafiltered (under nitrogen pressure) to separate the product and retain the enzyme (applied transmembrane pressure: 0.2 bar) and a new volume of substrate (30 mL) was added into the reactor using a peristaltic pump (Masterflex), to start the subsequent reaction cycle. The reaction solution was not completely ultrafiltered (10 mL remained as retentate). To remove the glucose present in the remaining retentate, washing steps using phosphate buffer (using 50 mM phosphate buffer pH 6.5) were carried out, adding 30 mL of buffer to the remaining retentate (10 mL) and ultrafiltrating the solution at 0.2 bar.

Some experiments (e.g., optimization of enzyme concentration, etc.) in a STR were also performed to study the effect of the competitive inhibition of the glucose. The operating conditions used for the batch STR were the same as the conditions used in the STR in the MBR.

The permeate, coming from every reaction cycle of the MBR and containing the purified OLA, was used as a dispersed phase for the ME process (Figure 2) and it was pressed under nitrogen gas (flux = 48 ± 8 Lh⁻¹ m⁻²) through the membrane. For this process, a hydrophobic SPG (Shirasu porous glass, SPG Technology Co., Ltd., Japan) membrane, with tubular configuration (0.4 μm, 8.7 mm inner diameter, 0.65 mm wall thickness, 31.3 cm2) was used. Ethyl acetate was used as the continuous phase and it was flushed, along the lumen side of the membrane, under pulsed flow, by a programmable peristaltic pump (Digi-Staltic double-Y Masterflex pump Micropump, model GJN23.7F1SAB1) (shear stress = 1.34 Pa). Aqueous droplets are formed at the pore outlet when the dispersed phase, containing OLA, meets the organic phase at the membrane surface. Owing to this process, OLA is extracted into the organic phase at the water-ethyl acetate interface. Due to the non-stabilized droplets of the formed emulsion (Piacentini et al., 2019), fast separation of the two phases was promoted, which guaranteed an easy recovery of the phase of interest. Dry OLA was produced at the end of the process by ethyl acetate evaporation.

The conversion (%) in the STR and the MBR was measured as the ratio between the mass of the OLA produced at the end of the cycle respect to the initial substrate mass.

The Extraction efficiency (EE) of OLA has been determined according to the following equation:

\[
EE = \frac{C_{EA} V_{EA}}{C_{H2O} V_{H2O}}
\]

Where CEA and VEA are OLA concentration in ethyl acetate and the volume of ethyl acetate were used as the continuous phase, respectively, while CH₂O and VH₂O are OLA concentration in water and the volume of water were used as the dispersed phase, respectively.

Generation of MCF-7 Tamoxifen Resistant Cell Line (MCF-7/TR)

The MCF-7/TR cell line was selected after the long-term cultivation of parental ERα+ MCF-7 cells. To induce resistance to tamoxifen, cells were exposed stepwise against increasing concentrations of 4-hydroxytamoxifen (4-OHT, Sigma-Aldrich, Italy), starting from 10⁻⁹M up to a final concentration of 10⁻⁸M. Cells were re-fed with a fresh growth medium containing the drug every 2–3 days. The acquired resistance to the antiestrogen was checked on a scheduled basis by the lack of any inhibitory effect on the proliferation of resistant cell lines compared to the parental ones (Supplementary Figures S1A,B, Supporting information).

Cell Cultures

MCF-7 and MDA-MB-231 BC cell lines and MCF10A (normal epithelial cells) were stored and used according to the supplier instructions. In all the solution fetal bovine serum (5%), l-Glutamine (1%), and penicillin-streptomycin (1 mg/ml) were present.

Cell lines were acquired and authenticated from Interlab Cell Line Collection (ICLC, Genova, Italy), they were tested monthly for negativity to Mycoplasma (MycoAlert, Lonza) and they were maintained as previously described (Pellegrino et al., 2018).
FIGURE 2 | Membrane system used to produce and extract oleuropein aglycone composed by a membrane bioreactor and a membrane emulsification process, PG, pressure gauges; V, valves; P, pump.

Cell Viability Assay (SRB)
A sulphorhodamine B assay (SRB) was used to evaluate the total biomass by staining cellular protein content. After treatment with vehicle (−) or OLA at 50 and 100 µM for 24, 48, and 72 h in 96-well plates, 10% trichloroacetic acid (TCA) for 1 h at 4°C was used to fix the cells. After fixation, SRB was used for staining (15 min) and the cells were washed 3 times with 1% acetic acid. Finally, the absorbance at 540 nm was measured by spectrophotometric analysis. GraphPad Prism 4 (GraphPad Software, Inc., San Diego, CA, United States) was used to calculate IC50 values.

Clonogenic Assay
Cells were plated in growth medium (GM) in 6-multiwell plates. The next day, they were treated with vehicle (−) or OLA at 50 and 100 µM. OLA treatment was renewed every 3 days. After 14 days, surviving colonies were stained with Crystal Violet and the images were acquired by Olympus BX51 inverted microscope. The obtained data by the Image J software were elaborated and normalized.

Soft Agar Anchorage-Independent Growth Assays
Cells were plated as previously described (Pellegrino et al., 2018). After 2 days, vehicle (−) or treatments (OLA at 50 and 100 µM) were added and replaced every 3 days. After 21 days, 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolio (MTT) was added to the plate and it was incubated for 4 h at 37°C. After overnight incubation at 4°C, colonies >50 µm diameter from triplicate assays were counted using an Olympus BX51 microscope.

Flow Cytometry
Cells after plating were treated with vehicle (−) or OLA at 50 and 100 µM for 24 h. The cells were harvested by trypsinization and resuspended in propidium iodide solution after treatment with RNase as described above (Rizza et al., 2016). FACScan flow cytometer (BD, United States) was used for measuring the DNA content was used and the data were acquired using CellQuest software. ModFit software was then used to determine the cell cycle profile was used.

Reverse Transcription and Real Time PCR (qRT-PCR)
After plating and starvation, the cells were treated with vehicle (−) or OLA at 50 and 100 µM for 12 and 24 h. TRIZOL reagent (Life Technologies, Italy) was used according to the manufacturer’s instructions for total RNA extraction. Total RNA (2 µg) was reverse transcribed with RETRO script kit (Ambion, Life Technologies, Italy). cDNA (diluted 1:3) was analyzed in the iCycler iQ™ detection system (Bio-Rad) in triplicate,
using SYBR green Master Mix (from Bio-Rad). Each sample was normalized vs. GAPDH mRNA content. All gene primer sequences including Cyclin D1, Cyclin E, p21cip1/waf1, p53, p27Kip1, Bcl-2, Bcl-XL, Bax, Bad, and GAPDH are shown in Supplementary Table S1 in the supplementary information. The results were calculated and expressed as previously reported (Catalano et al., 2007).

**Western Blot (WB) Analysis**

Equal amounts of proteins were resolved on SDS-page gel, as previously described (De Amicis et al., 2016). WB images are indicative of at least 3 different experiments.

Cyclin D1 (sc-718), cyclin E (sc-481), p21cip1/waf1 (p21) (sc-756), p53 (sc-126), p27Kip1 (p27) (sc-53871), Bcl-2 (sc-7382), Bcl-XL (sc-8392), Bax (sc-7480), Bad (sc-8044), and β-actin (sc-69879) were provided by Santa Cruz Biotechnology, Inc., Dallas, TX, United States, while PARP (#9532), Caspase3 (#9665), and Caspase8 (#9746) were purchased from Cell Signaling Technology, Netherlands, EU.

**Statistical Analysis**

ANOVA and Newman-Keuls’ testing were used to determine differences in means for statistical analysis. The band intensities in WBs represent the optical density and express the percentage vs. control. Data are shown as the mean ± SD of three different experiments, each performed in triplicate *p ≤ 0.05 vs. control.

**RESULTS AND DISCUSSION**

**Production of Oleuropein Aglycone by Integrated Membrane Process**

In this study, the glucose inhibition on the biocatalyst was controlled by adding a higher enzyme amount (enzyme: 1.5 $10^{-7}$ mol, substrate: 7.5 $10^{-5}$ mol, 2.5 mM) compared to the one previously reported (Ranieri et al., 2018), which achieved a conversion of about 93% in about 5 h in the STR. The same strategy was also used for other enzymatic systems in the presence of competitive inhibition (Andrić et al., 2010). However, the high price of the enzyme and the need for a subsequent product purification phase limited the development of this system on a large scale, therefore the recovery of the enzyme employing a membrane process is strongly recommended. To improve the conversion and purity of OLA, its production was carried out in an MBR consisting of an STR coupled with a UF process. To control the competitive inhibition caused by the co-product glucose (Ranieri et al., 2018), we studied the effect of glucose amount in contact with the enzyme, and its removal by UF (Table 1).

After each reaction cycle, the reaction mixture was not completely ultrafiltered (10 mL of retentate remained into the tank) to recover the enzyme. The use of this procedure, however, does not permit the complete removal of the glucose, causing competitive inhibition at the beginning of the next reaction cycle. This was confirmed (Table 1) by the continuous decrease of oleuropein conversion obtained in SERIE 1. Indeed, between the first and the second reaction cycle, the moles of glucose remained in contact with the enzyme were 2.43 $10^{-5}$ and consequently, we observed a decrease in the conversion of about 10% (Table 1). The moles of glucose, which were present before the third cycle, are almost doubled (4.6$10^{-5}$ moles) and this causes a significant drop in the degree of conversion (only 22%). To avoid this competitive inhibition, a washing step (with a buffer solution) between the cycles was added (Table 1, SERIE 2) This procedure combined with the new substrate addition allows maintaining the maximum conversion obtained in the first cycle and to overcome the inhibition of the glucose linked to the enzyme since the enzyme has more affinity for the substrate than the inhibitor ($K_a$: 1.17 mM, $K_i$: 1.93 mM, Ranieri et al., 2018). After the washing step (Table 1, SERIE 2) the glucose remained in the retentate solution is washed out, but not the enzyme that thanks to membrane process is retained and can be reused for the next reaction cycle.

As a result, it was possible to carry out five reaction cycles with no decay in conversion (Figure 3).

The optimized MBR was then integrated with a ME process to achieve the extraction of OLA in the ethyl acetate as reported in Piacentini et al. (2019). When the dispersed phase, containing OLA coming from the MBR permeated through the membrane of the ME system, water droplets are generated at the membrane

| TABLE 1 | Operating conditions used in the MBR and OLA conversion in the different reaction cycles in the MBR. |
|---------|---------------------------------|-------------------------------|-----------------------------|
| SERIE   | Operative conditions            | Conversion (%)                |
|---------|---------------------------------|-------------------------------|-----------------------------|
|         | Reaction cycles in the MBR     | Time contact between Enzyme/glucose (h) | Amount of glucose in contact with the enzyme prior to the substrate addition (mol) | Ultrafiltration with buffer to remove glucose in solution after UF process |
| 1       | 1                               | 5                             | 2.43$10^{-5}$*              | 93                           |
| 2       | 2                               | 3                             | 4.60$10^{-5}$*              | 82                           |
| 3       | 1                               | 5                             | 1.50$10^{-7}$*              | 23                           |
|         | 2                               |                               | x                           | 96                           |
|         | 3                               |                               | x                           | 93                           |
|         | 3                               |                               | x                           | 94                           |

*Moles of glucose bound to the enzyme, assuming that the glucose moles are equal to enzyme moles. **Moles of glucose remained in solution.
pore level that quickly separated from the continuous organic phases. The high surface area/volume ratio of the produced droplets allowed the continuous and high extraction (90%) of OLA in ethyl acetate under mild (e.g., low shear stress) operating conditions, from which the compound of interest could be easily recovered after solvent evaporation. The optimized integrated membrane process and in particular the strategy to decrease the inhibition effect of the glucose during the reaction, permitted to obtain a high purity of OLA in mild operative conditions. Besides, the enzyme which is one of the most expensive compounds in productive systems can be re-used for different reaction cycles with no decay in the activity.

Characterization of Obtained Oleuropein Aglycone

To check that the integrated membrane process had not altered the phytotherapeutic compound, the OLA produced by
FIGURE 5 | Effects of OLA compound on breast cancer growth. (A) SRB growth assays. MCF-10A, MCF-7/TR, and MDA-MB-231 cells treated with vehicle (−) or increasing doses (1-10-20-30-50-100-150 µM) of OLA for 24-48-72 h, as indicated. The results are expressed as % respect to control cells (−) ±S.D. relative to vehicle-treated cells and is representative of three different experiments each performed in triplicate ∗P < 0.05 treated vs vehicle-treated cells (−).

TABLE 2 | IC_{50} values of OLA for BCC.

| Cell lines | IC_{50} (µM) | 95% confidential interval |
|------------|--------------|---------------------------|
| MCF-7/TR   | 70           | 13–18.2                   |
| MDA-MB-231 | 53           | 15.5–28.7                 |

IC_{50} half-maximal inhibitory concentration.

HPLC, H1-NMR, and LC-MS were characterized. The H1-NMR spectrum (Supporting information) in CDCl₃ showed the aldehyde proton signals of the isomeric forms of OLA in the range 9.10–9.95 ppm. In particular, the signal of the monodialdehydic proton of the form D (scheme in Figure 1) (9.45 ppm), two aldehyde proton signals of the dialdehydic form C (9.52 and 9.60 ppm), and the aldehyde proton signal of the monodialdehydic form B (9.80 ppm). The signals (Supporting information) of hydrate forms B and D are less intense than the more lipophilic forms C and E.

The HPLC spectrum showed five signals reported to the forms A, B, C, D, and E (see Supplementary Figure S4). These five forms were detected using an elution gradient from 100% of H₂O 5 min to 35% of CH₃CN over 10 min, followed by 35–90% of B in 5 min.

LC-MS analysis (Figure 4) confirmed the presence of OLA isomers with an LC retention time of 4.364 min and an MS molecular ion peak of m/z = 401.1172 [M + Na]⁺.

The presence of all OLA isomers confirmed the suitability of the integrated membrane process for the production of this compound since we observed no modifications in the molecule structure after its production and extraction.

**Oleuropein Aglycone Inhibits Breast Cancer Cell (BCC) Growth**

The OLA produced by the integrated membrane process was subsequently used to evaluate the effect on BC viability (Figure 5) using MDA-MB-231 triple-negative and ER-α+ Tamoxifen resistant (MCF-7/TR) BCC.

The effects of different doses (1, 10, 20, 30, 50, 100, and 150 µM) of OLA were tested, using SRB assays on cell viability. Among the different doses, results demonstrated that 50 and 100 µM significantly inhibited cell viability in MDA-MB-231 and MCF-7/TR BC cells (Figure 5A).
FIGURE 6 | Effects of OLA compound on cell cycle distribution in breast cancer cells. MCF-7/TR cells, MDA-MB-231 cells, and MCF-10A were treated with vehicle (−) and 50 or 100 µM of OLA compounds for 24 h, stained with propidium iodide (PI) and analyzed on a FACScan flow cytometer. Quantitative analysis of percentage gated cells at G0/G1, S, G2/M, and sub-G0 phases are shown. ∗P < 0.05 OLA treated vs vehicle-treated cells (−).

| Cell cycle | G0/G1 (%) | S (%) | G2/M (%) |
|------------|-----------|-------|----------|
| Sub-G0 (%) |           |       |          |
| MCF-10A    |           |       |          |
| C          | 87.41±3.3 | 8.13±1.5 | 4.46±1.8 |
| OLA 50µM   | 85.76±3.4 | 8.57±1.2 | 5.47±1.3 |
| OLA 100µM  | 86.27±2.6 | 7.74±1.6 | 6.00±2.4 |
| MCF-7/TR   |           |       |          |
| C          | 69.54±3.6 | 20.29±1.6 | 9.77±2.4 |
| OLA 50µM   | 79.03±5.1 | 14.94±2.6 | 7.78±2.6 |
| OLA 100µM  | 12.50±1.8 |     |          |
| MDA-MB-231 |           |       |          |
| C          | 69.66±2.6 | 21.80±1.6 | 8.54±2.4 |
| OLA 50µM   | 69.09±3.1 | 20.98±1.8 | 10.83±2.1 |
| OLA 100µM  | 22.29±3.2 | 75.40±2.6 | 10.79±1.6 | 13.81±2.4 |

The IC50 (half-maximal inhibitory concentration) values for OLA are reported in Table 2. In normal breast epithelial cells (MCF-10A), the treatment with this compound elicits no considerable effects on cell viability (Figure 5A). Next, we evaluated: (1) the anti-proliferative effects induced by OLA on anchorage-dependent conditions (clonogenic assay, Supplementary Figure S6A); (2) the anchorage-independent BCC growth (soft agar assays) that mimic in vivo biologic features of tumors (Supplementary Figure S6B). According to the SRB assays OLA treatments, in a dose-dependent manner, significantly reduced colony formation in BCC tested (Supplementary Figures S6A,B).

In summary, these results suggest the capability of OLA to inhibit cell growth and proliferation in a selective manner on BCCs, without affecting normal breast epithelial cells (MCF-10A). Interestingly, OLA can exert an antiproliferative effect in Tamoxifen resistance conditions (MCF-7/TR), suggesting its use as an adjuvant strategy in the treatment of patients, which are refractory to hormonal therapies.

**Effects of Oleuropein Aglycone on Cell Cycle in BCCs**

To verify whether the inhibition of cell growth induced by the OLA compound was a perturbation of cell-cycle, Flow Cytometric cell-cycle analysis in all BCC after 24 h of treatment with vehicle (−) or OLA at 50 and 100 µM were performed. As shown in Figure 6A, OLA treatment induced a cell cycle arrest in the G0/G1 phase and a reduction of the fraction of cells in S-phase, as well as an increased % of apoptotic cells in both BCC.
FIGURE 7 | Effect of OLA compound on mRNA (A,C) and protein expression (B,D) in MCF-7/TR and MDA-MB-231 cells. (A,C) BCC was treated with vehicle (−) and 50 or 100 µM of OLA compound for 12 and 24 h before lysis. Cyclin D1 and E, p21^{Cip1/WAF1}, p53, and p27 mRNA content, evaluated by real-time RT-PCR. Each sample was normalized to its GAPDH mRNA content. The values represent the means ± S.D. of three different experiments, each performed in triplicate. (B,D) Equal amounts of total cellular protein extracts were analyzed for Cyclin D1 and E, p21^{Cip1/WAF1}, p53, and p27 and protein levels by immunoblotting analysis. B-actin was used as the loading control. The histograms represent the mean ± SD of three separate experiments in which band intensities were evaluated in terms of optical density arbitrary units (OD) and expressed as a percentage of control which was assumed to be 100%. *P < 0.05 OLA treated vs vehicle-treated cells (−).
FIGURE 8 | OLA triggers apoptotic cell death in breast cancer cells. (A) DNA laddering performed in MCF-7/TR and MDA-MB-231 cells treated with vehicle (−) and 50 or 100 µM of OLA for 48 h. One of three similar experiments is presented. (B) MCF-7/TR (left panel) and MDA-MB-231 (right panel) cells were treated with vehicle (−) and 50 or 100 µM of OLA for 48 h before lysis. Equal amounts of total cellular extracts were analyzed for PARP, caspase 3, and 8 protein expression from total cellular extracts. The histograms represent the mean ± SD of three separate experiments in which band intensities were evaluated in terms of optical density arbitrary units (OD) and expressed as a percentage of control which was assumed to be 100%. *P < 0.05 OLA treated vs vehicle-treated cells (−).
MCF-7/TR and (C) MDA-MB-231 cells were treated with vehicle (−) and 50 or 100 µM of OLA compound for 12 and 24 h before lysis. Bcl-2/Bcl-XL and Bax/Bad mRNA content, evaluated by real-time RT-PCR. Each sample was normalized to its GAPDH mRNA content. The values represent the means ± S.D. of three different experiments, each performed in triplicate.

(B) MCF-7/TR and (D) MDA-MB-231 cells were treated with vehicle (−) and 50 or 100 µM of OLA compound for 48 h before lysis. Immunoblots of Bcl-2/Bcl-XL and Bax/Bad were performed. B-actin was used as a loading control. The histograms represent the means ± S.D. of three separate experiments in which band intensities were evaluated in terms of optical density arbitrary units (OD) and expressed as a percentage of control which was assumed to be 100%. *P < 0.05 OLA treated vs vehicle-treated cells (−).
used. In MCF-10A, as expected, OLA at 50 and 100 µM did not elicit any effects on the cell cycle (Figure 6).

In apoptotic pathways, the activation axis including p21Cip1/WAF1, p53, p27, cyclin D1, and cyclin E are implicated in tumor pathogenesis and development of BC as well as in the resistance to anticancer therapy. In this context, the capability of a substance to interfere with this signaling could represent a promising option in investigating potential treatments for BC (Liu et al., 2015).

In order to elucidate the molecular mechanism through which the OLA compound induced the anti-proliferative effects and the capability to interfere in the pathways previously mentioned, the levels of mRNA and proteins associated with cell cycle-regulation were also examined (Figure 7).

Cells were exposed to the OLA compound at 50 and 100 µM for 12–24 and 48 h and the whole-cell extract were subjected to RT-PCR or immunoblotting analysis, respectively.

Similar to the results obtained on the cell cycle, these results indicated that a significant down-regulation of cyclin D1 and cyclin E expression in both BCC was observed. In the same experimental conditions, an up-regulation of p21Cip1/WAF1, p53, and p27 was evidenced (Figures 7A–D). These results confirm our hypothesis about the capability of OLA to interfere with the signaling, suggesting its apoptotic role in BCCs, including the tamoxifen resistant cells.

Oleuropein Aglycone Induces Apoptosis in Breast Cancer Cells

To corroborate the involvement of OLA in apoptosis, we first determined the fragmentation profile of genomic DNA (a typical biochemical hallmark of apoptotic cells death), in cells treated with OLA at 50 and 100 µM for 48 h, by DNA laddering. Chromosomal DNA extracted from MCF-7/TR and MDA-MB-231 cells revealed a marked DNA fragmentation consisting of multimers of 180–200 bp through agarose gel electrophoresis (Figure 8A).

Next, the proteolysis of PARP, a known substrate of effector caspases, and the cleavage of caspase 3 and 8 by the immunoblotting analysis were evaluated. Results showed an increased level of the proteolytic form of PARP and caspase 3 and 8, in both BC cells treated for 48 h with OLA at 50 or 100 µM, compared to vehicle-treated cells (Figure 8B). Increased expression of Bax/Bad and a down-regulation of Bcl-2/Bcl-XL both at mRNA and protein levels in BCC treated with OLA as reported (Figures 9A–D) were found. Finally, the apoptosis effect induced by OLA in both BCCs is demonstrated by the increased level of the proteolytic form of PARP, as a pivot target that signals the presence of DNA damage and facilitates DNA repair, as well as marked DNA fragmentation. Besides, the activation of Bax/Bcl-2 signaling could suggest the activation of the intrinsic apoptotic pathway. In conclusion, all the results obtained evidence that the inhibition of cell cycle progression through apoptosis induction could explain one of the mechanisms by which OLA exhibits its antiproliferative effects in human BCCs.

It is important to highlight that the same results were obtained using OLA aliquots produced/extracted at different times by the integrated membrane process. This suggests the suitability/reproducibility of the process for the production of OLA as well as its unmodified anticancer properties and stability.

CONCLUSION

In this work, an integrated membrane process was developed to produce OLA, an important phytotherapeutic compound generally present in olive oil.

The integrated membrane system was composed of an MBR, where the OLA was produced, and by a ME process, where the compound was extracted in a volatile green organic solvent. The substrate used in this reaction was oleuropein extracted from olive leaves by a sustainable method.

Under optimized conditions, we obtained an oleuropein conversion of about 93% for five consecutive reaction cycles and continuous extraction of OLA in the organic solvent (about 90%). The presence of all isomers of OLA, characterized by HPLC, H1-NMR, and LC-MS, confirmed the suitability of the integrated membrane process for the production/extraction of this compound since structural modification was observed.

The biosynthesized OLA was then tested as an antiproliferative drug toward two lines of BC cells: human ERα+ tamoxifen resistant (MCF-7/TR) and MDA-MB-231 (triple-negative). Results demonstrated that OLA caused a selective inhibition of cells growth just in BCC, without affecting the MCF-10A normal breast epithelial cells. It also induced G0/G1 cell cycle arrest, enhanced the CDK inhibitor p21Cip/WAF1, p27, p53 expression, and decreased cyclin D/E expression at both mRNA and protein levels. The increased cleavage/expression of proteins (PARP, caspase 3/8, Bax-Bad/Bcl-2-Bcl-XL) is typically observed during apoptotic phenomena and the significant DNA fragmentation also demonstrated the apoptotic activity of OLA in both the cell lines investigated.

This work proposed a productive strategy to obtain a compound with high therapeutic value by a sustainable technology, starting from waste/renewable material.

The mild production/extraction conditions used in the membrane process maintained the original properties of the phytotherapeutic compound. Based on the obtained results, OLA could be used for further studies as a potential tool that could be implemented for BC treatment, particularly to overcome the resistance of hormonal therapies.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

RM developed the membrane bioreactor of the combined membrane system, also wrote the article, combined all the different part of the manuscript and the different activities. EP developed the membrane emulsification process for the
REFERENCES

Abdelraheem, E. M. M., Busch, H., Hanefeld, U., and Tonin, F. (2019). Biocatalysis explained: from pharmaceutical to bulk chemical production. React. Chem. Eng. 4, 1878–1894. doi: 10.1039/c9re00301k

Abtin, M., Alivand, M. R., Khaniani, M. S., Bastami, M., Zaeifizadeh, M., and Derakhshan, S. M. (2018). Simultaneous downregulation of miR-21 and miR-155 through oleuropein for breast cancer prevention and therapy. J. Cell Biochem. 119, 7151–7165. doi: 10.1002/jcb.26754

Andrè, P., Meyer, A. S., Jensen, P. A., and Dam-Johansen, K. (2010). Reactor design for minimizing product inhibition during enzymatic lignocellulose hydrolysis II. Quantification of inhibition and suitability of membrane reactors. Biotechnol. Adv. 28, 407–425. doi: 10.1016/j.biotechadv.2010.02.005

Antognelli, C., Frosini, R., Santolla, M. F., Peirce, M. J., and Talesa, V. N. (2019). Anticancer properties of the oleuropein aglycone produced by an ancient enzyme. Oxid. Med. Cell Longev. 2019:6592875. doi: 10.1155/2019/6592875

Barbaro, B., Toietta, G., Maggio, R., Arciolo, M., Tarocchi, M., Galli, A., et al. (2014). Effects of the olive-derived polyphenol oleuropein on human health. Intern. J. Mol. Sci. 15, 18508–18524. doi: 10.3390/ijms15101850

Bayat, S., Mansoori Derakhshan, S., Mansoori Derakhshan, N., Shekari Khaniani, M., and Alivand, M. R. (2019). "Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells. J. Cell Biochem. 120, 9172–9180. doi: 10.1002/jcb.28193

Carnero, A., Garcia-Mayea, Y., Mir, C., Lorente, J., Rubio, I. T., and Lleonart, T. M. (2016). The cancer stem-cell signaling network and resistance to therapy. Cancer Treat. Rev. 49, 25–36. doi: 10.1016/j.ctrv.2016.07.001

Casaburi, I., Puoci, F., Chimento, A., Sirianni, R., Ruggiero, C., Avena, P., et al. (2013). Potential of olive oil phenols as chemopreventive and therapeutic agents against cancer: a review of in vitro studies. Mol. Nutr. Food Res. 57, 71–83. doi: 10.1002/mnfr.201200503

Catalano, S., Rizza, P., Gu, G., Barone, I., Giordano, C., Marsico, S., et al. (2007). Oleuropein-induced apoptosis is mediated by mitochondrial glyoxalase 2 in NSCLC A549 cells: a mechanistic inside and a possible novel nonenzymatic role for an ancient enzyme. Oxid. Med. Cell Longev. 2007:985691. doi: 10.1155/2007/985691

De Amicis, F., Guido, C., Santoro, M., Giordano, F., Donà, A., Rizza, P., et al. (2016). Ligand activated progesterone receptor B drives autophagy-senescence transition through a Beclin-1/Bcl-2 dependent mechanism in human breast cancer cells. Oncotarget 23, 57955–57969. doi: 10.18632/oncotarget.10799

De Nino, A., Mazzotti, F., Perri, E., Procopio, A., Raffaelli, A., and Sindona, G. (2000). Virtual freezing of the hemiacetal-aldehyde equilibrium of the aglycones of oleuropein and ligstroside present in olive oils from Coratina and Coratina cultivar by ionspray ionization tandem mass spectrometry. J. Mass Spectrom. 35, 461–467. doi: 10.1002/(sici)1096-9888(200003)35:3<461::aid-jms961>3.0.co;2-e

Di Donna, L., Benabdelkhalim, H., Mazzotti, F., Napoli, A., Nardi, M., and Sindona, G. (2011). High-throughput assay of oleopentanedialdehydes in extra virgin olive oil by the UHPLC-ESI-MS/MS and isotope dilution methods. Anal. Chem. 83, 1990–1995. doi: 10.1021/ac200152r

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int. J. Cancer 136, E359–E386.

Galiano, V., and Villalain, J. (2015). Oleuropein aglycone in lipid bilayer membranes. A molecular dynamics study. Biochim. Biophys. Acta 1848, 2849–2858. doi: 10.1016/j.bbamem.2015.08.007

Giorno, F., Mazzei, R., and Giorno, L. (2013). Purification of triacylglycerols for biodiesel production from Nannochloropsis microalgae by membrane technology. Bioresour. Technol. 140, 172–178. doi: 10.1016/j.biortech.2013.04.073

Han, J., Talorette, T. P., Yamada, P., and Isoda, H. (2009). Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer MCF-7 cells. Cytotechnology 59, 45–53. doi: 10.1007/s10616-009-9191-2

Impellizzeri, D., Esposito, E., Mazzen, E., Paterniti, I., Di Paola, R., Bramanti, P., et al. (2011). The effects of oleuropein aglycone, an olive oil compound, in a mouse model of carrageenan-induced pleurisy. Clin. Nutr. 30, 533–540.

Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., et al. (2015). Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J. Natl. Cancer Instit. 107:dvj048

Leri, M., Nosí, D., Natalello, A., Porcarì, R., Ramazzotti, M., Chiti, F., et al. (2016). The polyphenol Oleuropein aglycone hinders the growth of toxic transferytin amyloid assemblies. J. Nutr. Biochem. 30(Suppl. C), 153–166. doi: 10.1016/j.jnutbio.2015.12.009

Lim, H. J., Crowe, P., and Yang, J. L. (2015). Current clinical regulation of PI3K/Pten/Akt/mTOR signalling in treatment of human cancer. J. Cancer Res. Clin. Oncol. 141, 671–689. doi: 10.1007/s00432-014-1803-3

Liu, L., Ahn, K. S., Shammu, M. K., Wang, H., Shen, H., Arfuso, F., et al. (2019). Oleuropein induces apoptosis via abrogating NF-κB activation cascade in estrogen receptor-negative breast cancer cells. J. Cell Biochem. 120, 4504–4513. doi: 10.1002/jcb.27738

Macedonio, F., and Drioli, E. (2017). Membrane engineering for green process engineering. Engineering 3, 290–298. doi: 10.1016/leng.2017.03.026

Mazzei, R., Drioli, E., and Giorno, L. (2010a). "Biocatalytic membranes and membrane bioreactors," in Comprehensive Membrane Science and Engineering, eds E. Drioli and L. Giorno (Cham: Springer), 195–212. doi: 10.1007/978-0-85709-0058-3

Mazzei, R., Drioli, E., and Giorno, L. (2010b). Biocatalytic membrane reactor and membrane emulsification concepts combined in a single unit to assist production and separation of water unstable reaction products. J. Membr. Sci. 352, 166–172. doi: 10.1016/j.memsci.2010.02.011

Mazzei, R., Drioli, E., and Giorno, L. (2012). Membrane enzyme reactor with heterogenized β-glucosidase to obtain phytotherapeutic compound: optimization study. J. Membr. Sci. 390–391, 121–129. doi: 10.1016/j.memsci.2011.11.028

Mazzei, R., Giorno, L., Piacentini, E., Mazzucca, S., and Drioli, E. (2009). Kinetic study of a biocatalytic membrane reactor containing immobilized β-glucosidase for the hydrolysis of oleuropein. J. Membr. Sci. 339, 215–223. doi: 10.1016/j.memsci.2009.04.053

Mazzei, R., Piacentini, E., Drioli, E., and Giorno, L. (2013). "Membrane bioreactors for green processing in a sustainable production system," in Process Intensification for Green Chemistry: Engineering Solutions for Sustainable Chemical Processing, eds K. Boodhoo and A. Harvey (Hoboken, NJ: John Wiley & Sons, Ltd).

Mazzei, R., Piacentini, E., Gebreyohannes, A. Y., and Giorno, L. (2017). Membrane bioreactors in food, pharmaceutical and biofuel applications: state of the art, progresses and perspectives. Curr. Organ. Chem. 21, 1671–1701.
Menendez, J. A., Vazquez-Martin, A., Colomer, R., Brunet, J., Carrasco-Panconorro, A., Garcia-Villalba, R., et al. (2007). Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. *BMC Cancer* 7:80. doi: 10.1186/1471-2407-7-80

Menendez, J. A., Vazquez-Martin, A., Garcia-Villalba, R., Carrasco-Panconorro, A., Oliveras-Ferraros, C., Fernandez-Gutierrez, A., et al. (2008). Anti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO). *BMC Cancer* 8:377. doi: 10.1186/1471-2407-7-377

Omogbadegun, Z. O. (2013). Medicinal plants-based foods for breast cancer treatment: an ethnobotanical survey and digitization. *Intern. J. Med. Plants Altern. Med.* 1, 137–163.

Pantano, D., Luccarini, I., Nardiello, P., Servili, M., Stefani, M., Casamenti, F., et al. (2017). Oleuropein aglycone and polyphenols from olive mill waste water ameliorate cognitive deficits and neuropathology. *Br. J. Clin. Pharmacol.* 83, 54–62. doi: 10.1111/bcp.12993

Pellegrino, M., Rizza, P., Nigro, A., Ceraldi, R., Ricci, E., Perrotta, I., et al. (2018). FoxO3a mediates the inhibitory effects of the antiepileptic drug lamotrigine on breast cancer growth. *Mol. Cancer* Res. 16, 923–934. doi: 10.1158/1541-7786.MCR-17-0662

Piacentini, E., Mazzei, R., Bazzarelli, F., Ranieri, G., Poerio, T., and Giorno, L. (2019). Oleuropein aglycone production and formulation by integrated membrane process. *Ind. Eng. Chem. Res.* 58, 16813–16822. doi: 10.1021/acs.iecr.9b03210

Piacentini, E., Mazzei, R., and Giorno, L. (2017). Membrane bioreactors for pharmaceutical applications: optically pure enantiomers production. *Curr. Pharm. Design* 23, 250–262. doi: 10.2174/1381612823666161123143512

Procopio, A., Alcaro, S., Nardi, M., Oliverio, M., Ortufo, F., Sacchetta, P., et al. (2009). Synthesis, biological evaluation, and molecular modeling of oleuropein and its semisynthetic derivatives as cyclooxygenase inhibitors. *J. Agric. Food Chem.* 57, 11161–11167. doi: 10.1021/jf9033305

Ranieri, G., Mazzei, R., Poerio, T., Bazzarelli, F., Wu, Z., Li, K., et al. (2018). Biorefinery of olive leaves to produce dry oleuropein aglycone: use of homemade ceramic capillary biocatalytic membranes in a multiphase system. *Chem. Eng. Sci.* 185, 149–156. doi: 10.1016/j.ces.2018.03.053

Rizza, P., Pellegrino, M., Caruso, A., Iacopetta, D., Sinicropi, M. S., Rault, S., et al. (2016). 3-(Dipropylamino)-5-hydroxybenzofuro[2,3-f]quinazolin-1(2H)-one (DPA-HBFQ-1) plays an inhibitory role on breast cancer cell growth and progression. *Eur. J. Med. Chem.* 107, 275–287. doi: 10.1016/j.ejmech.2015.11.004

Sharma, R., Tobin, P., and Clarke, S. J. (2005). Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. *Lancet Oncol.* 6, 93–102. doi: 10.1016/S1470-2045(05)01735-3

Sirianni, R., Chimento, A., De Luca, A., Casaburi, I., Rizza, P., Onofrio, A., et al. (2010). Oleuropein and hydroxytyrosol inhibit MCF-7 breast cancer cell proliferation interfering with ERK1/2 activation. *Mol. Nutr. Food Res.* 54, 833–840. doi: 10.1002/mnfr.200900111

Vidal, S. J., Rodriguez-Bravo, V., Galsky, M., Cordon-Cardo, C., and Domingo-Domenech, J. (2014). Targeting cancer stem cells to suppress acquired chemotherapy resistance. *Oncogene* 33, 4451–4463. doi: 10.1038/onc.2013.411

Woodley, J. M. (2008). New opportunities for biocatalysis: making pharmaceutical processes greener. *Trends Biotechnol.* 26, 321–327. doi: 10.1016/j.tibtech.2008.03.004

Xu, F., Li, Y., Zheng, M., Xi, X., Zhang, X., and Han, C. (2018). Structure properties, acquisition protocols, and biological activities of oleuropein aglycone. *Front. Chem.* 6:239. doi: 10.3389/fchem.2018.00239

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2020 Mazzei, Piacentini, Nardi, Poerio, Bazzarelli, Procopio, Di Gioia, Rizza, Ceraldi, Morelli, Giorno and Pellegrino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**